William Blair analyst Andy Hsieh downgraded Aravive to Market Perform from Outperform after the Phase 3 trial of the company’s GAS6-AXL pathway inhibitor, batiraxcept, in combination with chemotherapy for platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival. The analyst cites a lack of near-term clinical catalysts that could materially reshape investors’ perspective on batiraxcept and the company’s limited cash runway for the downgrade.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARAV: